Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shengjing Hospital
With
Jiangsu HengRui Medicine Co., Ltd.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Confirmed histologic diagnosis of invasive adenocarcinoma of the breast
ER, PR and HER2 testing, and
TNBC patients （ HER2-neu 0-1+ by IHC or FISH-negative by ASCO CAP guidelines）
ER-positive and HER2-negative breast cancer
tumor measuring ≥2 cm in maximal diameter as measured by any available standard of care imaging (mammogram, breast ultrasound, breast MRI)
Any nodal status
ECOG Performance Status of 0 -1
Screening laboratory values must meet the following criteria:
i. Absolute neutrophil count (ANC) ≥1.5 × 109/L ii. Platelets ≥100 × 109/L iii. Hemoglobin ≥ 10.0 g/dl for TNBC, ≥ 10.0 g/dl for HR+/HER2-BC iv. Serum creatinine ≤1.5 x upper limit of normal (ULN) v. AST ≤ 2.5 xULN vi. ALT ≤ 2.5 x ULN vii. Total bilirubin ≤ 2.5 xULN viii left ventricular ejection fraction ≥ 50%.
You may not be if
Any kind of prior treatment for breast cancer, including chemotherapy, radiotherapy, endocrine therapy and so on
Inflammatory breast cancer
Pregnant and lactating women;
distant metastasis
patients who have participated in other clinical trials.
Clareo Health | Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
